Ricevi le ultime notizie sulle azioni Biohaven con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BHVN

Ultime notizie per

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

Biohaven Ltd

News

Legal

Press Releases

Deadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVN

BIOHAVEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Biohaven Investors of the September 12th Deadline to File in the Class Action Lawsuit

Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Small Cap

Deadline Soon: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Lost Money on Biohaven Ltd. (BHVN) Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit

Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven

BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

BHVN

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Celcuity

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Dyne Therapeutics

89bio

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Immunome

Janux Therapeutics

MannKind

NuCana

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Stoke Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Biohaven Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO